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SIONS: While women were less costly to treat, this difference
was not attributable to medication efﬁcacy or observable patient
characteristics. Medication compliance may be a factor and
merits further investigation.
PCV20
RATES OF HYPERTENSION-RELATED MEDICAL AND
PRESCRIPTION UTILIZATION AND COSTS IN A STATE
MEDICAID POPULATION
Mody RR, Smith MJ
West Virginia University, Morgantown, WV, USA
Hypertension, a major risk factor for cardiovascular diseases
such as stroke and myocardial infarction, affects approximately
50 million adults in the United States. OBJECTIVES: To assess
utilization and costs for hypertension-related medical services
and pharmacotherapy among recipients in a state Medicaid pop-
ulation. METHODS: Medical services claims with a primary
ICD-9 CM diagnosis code for hypertension (401.xx) during cal-
endar year 2002, for recipients between 15 and 64 years of age
were extracted. Unique recipient identiﬁers obtained from these
claims were then used to extract hypertension-related prescrip-
tion claims. Medicaid reimbursements were used to calculate
costs for outpatient, ED and prescription use; Medicare DRG
average reimbursement amounts were used to calculate hospital
costs. RESULTS: Overall hypertension prevalence was 10.7%
among Medicaid recipients. Of the 17,610 recipients identiﬁed,
25% received single antihypertensive drug therapy, 60% received
two or more antihypertensive drugs and 15% had no prescrip-
tion claims for antihypertensive drugs. Of those recipients receiv-
ing single drug therapy (n = 4,478), 30% received angiotensin
converting enzyme inhibitors, 22% received beta blockers, 18%
received calcium channel blockers, 15% received diuretics, 10%
received angiotensin receptor blockers, and 5% received other
classes of drugs such as alpha1 blockers, centrally acting alpha2
agonists, and vasodilators. The rates of hospitalization, ED and
outpatient visits were 5/10,000 recipients, 43/10,000 recipients,
and 173/1000 recipients, respectively. The mean cost per hospi-
talization, ED and outpatient visit was $2422 (SD = $359), $188
(SD = $211) and $58 (SD = $61), respectively. Total hyperten-
sion-related expenditures to Medicaid were: $193,776 for hos-
pitalizations, $133,779 for ED use, $2,296,746 for outpatient
use and $6,744,515 for prescription drugs. CONCLUSIONS:
Results showed that a majority of recipients with hypertension
received two or more antihypertensive drugs. Hypertension is
responsible for a substantial economic burden to Medicaid with
outpatient use accounting for most medical visits and prescrip-
tion drugs accounting for most dollars.
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OBJECTIVES: To determine the rate in which patients treated
with statins received a concomitant potentially interacting 
medication (PIM) and the cost associated with receiving a PIM.
METHODS: New users of atorvastatin, pravastatin or simvas-
tatin during the time period 01.01.00–12.31.01 were selected
from a claims database for a large U.S. health plan. Adult sub-
jects were included if they had 24 months of continuous eligi-
bility surrounding their ﬁrst study medication claim, and had no
evidence of switching to another statin in the 12-month follow-
up period. To control for potential selection bias and confound-
ing by indication, two propensity score matching processes were
used. The ﬁrst matched subjects based on statin therapy and the
second matched subjects based on receipt of a PIM. Subjects
were followed for 12 months to measure total pharmacy and
medical utilization and cost. Logistic regression was used to
determine the risk of receiving a PIM and log-linear ordinary
least-squares regression was used to determine the cost differ-
ence. RESULTS: A total 48,958 subjects met the inclusion/
exclusion criteria. Of the 23,594 subjects who were matched on
statin therapy propensity scores, 30% of atorvastatin, 3% of
pravastatin and 32% of simvastatin subjects received a PIM in
the follow-up period. Relative to pravastatin, the odds ratios for
receiving a PIM (and 95%CI) were 15.3 (13.3–17.6) for ator-
vastatin and 16.3 (14.1–18.8) for simvastatin. 13,916 subjects
were matched on receipt of a PIM. Subjects receiving a PIM had
32% (p < 0.0001) greater medical and 50% (p < 0.0001) greater
pharmacy cost in the follow-up period than those that did not.
CONCLUSIONS: A signiﬁcant number of subjects receiving
atorvastatin or simvastatin also received a concomitant poten-
tially interacting medication. Subjects receiving PIMs were of sig-
niﬁcantly greater cost to the health care system. Opportunity
exists to educate providers and decision-makers regarding 
the prevalence and impact of potential statin medication 
interactions.
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OBJECTIVES: To assess direct (medical and drug) annual costs
and associated comorbidities of atrial ﬁbrillation (Aﬁb) in dif-
ferent patient age groups. METHODS: The study sample was
identiﬁed from an employer claims database including medical,
drug, and disability claims for approximately 2 million enrollees
over the period 1999–2002. Patients with at least two Aﬁb diag-
noses were included in the sample (n = 17,781). A non-Aﬁb
control sample was randomly selected with a 1 :1 ratio, with
patient characteristics (i.e. age, gender, region of residence)
matched to the Aﬁb sample. All patients were used in comor-
bidities analyses, while only those patients under age 65 (n =
3952) were used in cost analyses. Patients were stratiﬁed in two
age groups (<45, 45–64). To assess excess annual cost and
comorbidities, we compared Aﬁb patients to control patients.
Cost analyses were conducted from a third party payer’s 
perspective. All costs were adjusted to 2002 dollars using CPI.
Statistical signiﬁcance was measured by T-tests for cost compar-
isons, or Chi-square tests for comorbidities comparisons.
RESULTS: The average excess annual medical cost of an Aﬁb
patients was $12056 (P < 0.01). For patients in the older (45–64)
and younger (<45) age groups, the excess annual medical costs
of Aﬁb were $12,280 (P < 0.01) and $9969 (P < 0.01), respec-
tively. The difference between the excess costs for the two age
groups was not signiﬁcant. The most expensive cost component
of Aﬁb was inpatient hospitalization. Aﬁb was associated with
increased risk of atrial ﬂutter (Relative Risk (RR) = 140, P <
0.01), other arrhythmias/conduction disorders (RR = 7, P <
0.01), heart failure (RR = 8, P < 0.01), stroke (RR = 4, P < 0.01),
heart attack (RR = 4, P < 0.01), depressive disorders (RR = 2, P
< 0.01), and generalized anxiety disorder (RR = 2, P < 0.01).
CONCLUSIONS: The study found that Aﬁb is a costly disease
associated with high risk of heart attack, heart failure, stroke,
arrhythmias, depression, and generalized anxiety disorder. There
is no signiﬁcant cost difference across age groups.
